Novartis Sues Par Over Dementia Patch Generic

Law360, New York (August 23, 2013, 3:14 PM EDT) -- Novartis AG hit rival Par Pharmaceutical Inc. with a suit in Delaware federal court Thursday, accusing Par’s proposed generic version of dementia treatment Exelon of infringing a patent covering the drug.

According to the Swiss pharmaceutical giant, Woodcliff Lake, N.J.-based Par’s planned 13.3-milligram generic rivastigmine transdermal patches infringes upon U.S. Patent Number 6,335,031, a patent jointly owned by Novartis and German transdermal patch specialist LTS Lohmann Therapie-Systeme AG.

“There is a substantial and immediate controversy between plaintiffs and Par concerning the '031 patent,” the complaint said....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.